Genenta Science S.p.A. SEC filings GNTA

Genenta Science S.p.A. has 119 filings in SEC EDGAR's recent list, going back to Mar 1, 2021. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026.

Genenta Science S.p.A. SEC filings
Form Description Filed Period
EFFECT Filing May 24, 2023 —
CORRESP Letter to the SEC May 22, 2023 —
UPLOAD Letter from the SEC May 22, 2023 —
SEC STAFF LETTER Filing Dec 16, 2021 —
EFFECT Filing Dec 14, 2021 —
CERT Filing Dec 14, 2021 —
CORRESP Letter to the SEC Dec 10, 2021 —
CORRESP Letter to the SEC Dec 10, 2021 —
CORRESP Letter to the SEC Dec 3, 2021 —
8-A12B Filing Dec 1, 2021 —
CORRESP Letter to the SEC Nov 24, 2021 —
UPLOAD Letter from the SEC Nov 12, 2021 —
DRSLTR Filing Oct 29, 2021 —
DRS/A Filing Oct 29, 2021 —
SEC STAFF LETTER Filing Oct 21, 2021 —
UPLOAD Letter from the SEC Oct 21, 2021 —
DRS/A Filing Oct 4, 2021 —
UPLOAD Letter from the SEC Jun 3, 2021 —
DRS/A Filing May 19, 2021 —
DRSLTR Filing May 19, 2021 —
UPLOAD Letter from the SEC May 7, 2021 —
DRSLTR Filing Apr 22, 2021 —
DRS/A Filing Apr 22, 2021 —
UPLOAD Letter from the SEC Mar 29, 2021 —
DRS Filing Mar 1, 2021 —

Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
GNTA (Nasdaq)
Incorporated in
Italy
Headquarters
Milan, Italy
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1838716
Former names
Genenta Science S.r.l. (until May 19, 2021)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.